{
    "clinical_study": {
        "@rank": "82253", 
        "acronym": "DG Post-Partum", 
        "arm_group": [
            {
                "arm_group_label": "GD diagnosis before 24 weeks", 
                "description": "Patients in this group are diagnosed with gestational diabetes (GD) before 24 weeks of amenorrhea by means of a fasting blood glucose test >= 0.92 g/l.\nIntervention: Post-partum oral glucose tolerance test"
            }, 
            {
                "arm_group_label": "GD diagnosed at 24 to 28 weeks", 
                "description": "Patients in this group are diagnosed with gestational diabetes between 24 and 28 weeks of amenorrhea based on a normal fasting blood glucose level before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test between 24 and 28 weeks of amenorrhea.\nIntervention: Post-partum oral glucose tolerance test"
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective of the study is to estimate and compare the percentage of patients with\n      abnormal glucose metabolism at 4-12 weeks postpartum between two groups: patients diagnosed\n      with gestational diabetes before or after 24 weeks of pregnancy. Abnormal glucose metabolism\n      is defined as type 2 diabetes, glucose intolerance or impaired fasting glucose."
        }, 
        "brief_title": "Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Gestational Diabetes", 
            "Type 2 Diabetes", 
            "Glucose Intolerance"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Diabetes, Gestational", 
                "Glucose Intolerance"
            ]
        }, 
        "detailed_description": {
            "textblock": "The secondary objectives of this study are to compare between the two groups:\n\n      A. the rate of type 2 diabetes only, glucose intolerance only, impaired fasting glucose\n      only, and patients requiring insulin at 4-12 weeks postpartum\n\n      B. rates of maternal and obstetric complications\n\n      C. risk factors (age, body mass index, personal history of gestational diabetes or\n      macrosomia, first degree family history of diabetes).\n\n      D. For fasting glucose done before 24SA, we will calculate the optimal threshold for\n      predicting abnormal glucose metabolism in the immediate postpartum period among women with\n      gestational diabetes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient must have given her informed and signed consent\n\n          -  The patient must be insured or beneficiary of a health insurance plan\n\n          -  The patient is available for 10 months of follow-up\n\n          -  The patient is pregnant and consulting before 24 weeks of amenorrhea AND has at least\n             one of the following risk factors: age > 35 years; body mass index > 25; family\n             history of type 2 diabetes; history of gestational diabetes; history of macrosomia.\n\n          -  The patient has a fasting blood glucose level >= 0.92 g/l before 24 weeks of\n             amenorrhea OR a fasting blood glucose level < 0.92 g/l before 24 weeks of amenorrhea\n             AND an abnormal oral glucose tolerance test (75 g of glucose) between 24 and 28 weeks\n             of amenorrhea (normal values are set at T0 < 0.92 g/l; T60 < 1.80 g/l; T120 < 1.53\n             g/l).\n\n        Exclusion Criteria:\n\n          -  The patient is participating in another study\n\n          -  The patient is in an exclusion period determined by a previous study\n\n          -  The patient is under judicial protection, under tutorship or curatorship\n\n          -  The patient refuses to sign the consent\n\n          -  It is impossible to correctly inform the patient\n\n          -  The patient cannot read French\n\n          -  The patient has a known history of type 2 diabetes\n\n          -  The patient is diagnosed with type 2 diabetes during pregnancy (fasting blood glucose\n             level > 1.26 g/l)\n\n          -  The patient has a contra-indication for a treatment necessary for this study\n\n          -  The patient is taking chronic or intermittent oral or inhaled corticosteroids, or a\n             \u03b22 agonist treatment for a previous disease or a disease discovered during pregnancy\n             within one week preceding the fasting glucose or oral glucose tolerance test."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study population is composed of pregnant women consulting before 24 weeks of\n        amenorrhea and who have at least one of the following risk factors: age > 35 years; body\n        mass index > 25; a family history of type 2 diabetes; a history of gestational diabetes or\n        macrosomia."
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839448", 
            "org_study_id": "AOI/2012/VC-01", 
            "secondary_id": "2013-A00277-38"
        }, 
        "intervention": {
            "arm_group_label": [
                "GD diagnosis before 24 weeks", 
                "GD diagnosed at 24 to 28 weeks"
            ], 
            "description": "All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy.  Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.", 
            "intervention_name": "Post-partum oral glucose tolerance test", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "post partum diabetes", 
            "impaired fasting glucose"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }, 
                    "name": "CHU de Montpellier - H\u00f4pital Lapeyronie"
                }, 
                "investigator": [
                    {
                        "last_name": "C\u00e9cile Brunet, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Eric Renard, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier Cedex 5", 
                        "country": "France", 
                        "zip": "34295"
                    }, 
                    "name": "CHU de Montpellier - H\u00f4pital Arnaud de Villeneuve"
                }, 
                "investigator": {
                    "last_name": "Pierre Boulot, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "N\u00eemes Cedex 9", 
                        "country": "France", 
                        "zip": "30029"
                    }, 
                    "name": "CHU de N\u00eemes - H\u00f4pital Universitaire Car\u00e9meau"
                }, 
                "investigator": [
                    {
                        "last_name": "Val\u00e9ria Cosma, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anne-Marie Guedj, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Michel Rodier, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Pierre Mar\u00e8s, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "2", 
        "official_title": "Frequency of Abnormal Glucose Metabolism (Diabetes, Impaired Glucose Tolerance, Impaired Fasting Glucose) in the Immediate Postpartum Period Following Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation", 
        "other_outcome": [
            {
                "measure": "Age", 
                "safety_issue": "No", 
                "time_frame": "baseline (day 0)"
            }, 
            {
                "measure": "Body mass index", 
                "safety_issue": "No", 
                "time_frame": "baseline (day 0)"
            }, 
            {
                "measure": "Number of pregnancies", 
                "safety_issue": "No", 
                "time_frame": "baseline (day 0)"
            }
        ], 
        "overall_contact": {
            "email": "anne.marie.guedj@chu-nimes.fr", 
            "last_name": "Anne-Marie Guedj, MD", 
            "phone": "+33.(0)4.66.68.33.21"
        }, 
        "overall_contact_backup": {
            "email": "carey.suehs@chu-nimes.fr", 
            "last_name": "Carey M Suehs, PhD", 
            "phone": "+33.(0)4.66.68.67.88"
        }, 
        "overall_official": [
            {
                "affiliation": "Centre Hospitalier Universitaire de N\u00eemes", 
                "last_name": "Val\u00e9ria Cosma, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Centre Hospitalier Universitaire de N\u00eemes", 
                "last_name": "Anne-Marie Guedj, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Committee for the Protection of Personnes", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Includes type 2 diabetes, glucose intolerance and impaired fasting glucose", 
            "measure": "Presence/absence of abnormal glucose metabolism", 
            "safety_issue": "No", 
            "time_frame": "4 to12 weeks post-partum"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839448"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Presence/absence of type 2 diabetes", 
                "safety_issue": "No", 
                "time_frame": "4 to 12 weeks post partum"
            }, 
            {
                "measure": "Presence/absence of glucose intolerance", 
                "safety_issue": "No", 
                "time_frame": "4 to 12 weeks post-partum"
            }, 
            {
                "description": "American definition: defined as between 1 and 1.26 g/l", 
                "measure": "Presence/absence of impaired fasting glucose", 
                "safety_issue": "No", 
                "time_frame": "4 to12 weeks post-partum"
            }, 
            {
                "description": "European definition: defined as between 1.1 and 1.26 g/l", 
                "measure": "Presence/absence of impaired fasting glucose", 
                "safety_issue": "No", 
                "time_frame": "4 to12 weeks post-partum"
            }, 
            {
                "measure": "Patient requiring insulin: yes/no", 
                "safety_issue": "No", 
                "time_frame": "4 to12 weeks post-partum"
            }, 
            {
                "description": "This includes a yes/no response for each of the following: caesarean section, hypertension, preeclampsia, urinary tract infection, macrosomia, dystocia, neonatal transfer, respiratory distress, threat of premature birth.", 
                "measure": "Presence/absence of complications", 
                "safety_issue": "No", 
                "time_frame": "4 to12 weeks post-partum"
            }, 
            {
                "measure": "Baby's weight at birth (kg)", 
                "safety_issue": "No", 
                "time_frame": "4 to 12 weeks post-partum"
            }, 
            {
                "measure": "Weeks of amenorrhea (duration of pregnancy in weeks/ gestational age)", 
                "safety_issue": "No", 
                "time_frame": "4 to 12 weeks post-partum"
            }, 
            {
                "measure": "Patient was older than 35 years of age at beginning of pregnancy? yes/no", 
                "safety_issue": "No", 
                "time_frame": "baseline (day 0)"
            }, 
            {
                "measure": "Body mass index > 25 at beginning of pregnancy? yes/no", 
                "safety_issue": "No", 
                "time_frame": "baseline (day 0)"
            }, 
            {
                "measure": "First degree family history of type 2 diabetes? yes/no", 
                "safety_issue": "No", 
                "time_frame": "baseline (day 0)"
            }, 
            {
                "measure": "History of gestational diabetes? yes/no", 
                "safety_issue": "No", 
                "time_frame": "baseline (day 0)"
            }, 
            {
                "measure": "History of macrosomia? yes/no", 
                "safety_issue": "No", 
                "time_frame": "baseline (day 0)"
            }, 
            {
                "measure": "Fasting glucose (g/l)", 
                "safety_issue": "No", 
                "time_frame": "before 24 weeks of amenorrhea"
            }, 
            {
                "measure": "Oral glucose tolerance test results if necessary", 
                "safety_issue": "No", 
                "time_frame": "24 to 28 weeks of amenorrhea"
            }
        ], 
        "source": "Centre Hospitalier Universitaire de N\u012bmes", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire de N\u012bmes", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}